Plain-English translation of NCT07440225 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Macular Degeneration research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called (also known as MK-8748 or EYE201) to treat wet age-related macular degeneration, a condition where abnormal blood vessels grow under the macula—the part of your eye responsible for sharp, central vision. Researchers want to find out if this medication works as well as , a treatment already approved for this condition. The trial will compare two different doses of the new medication against the standard treatment.
Current treatments for wet macular degeneration don't work equally well for everyone, and doctors need more options to help patients preserve their vision. This trial exists to see whether this new medication could be an effective alternative.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll receive injections directly into your eye every 4 weeks for the first 12 weeks, then every 8 weeks after that through week 48. After week 48, your treatment schedule may be adjusted based on how well you're responding to the medication. The entire trial lasts about 2 years, and you'll have regular eye exams and vision tests to monitor how the treatment is working.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States